Biogen vs Gilead Sciences
Biogen (BIIB) and Gilead Sciences (GILD) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $33.9B
- Last close
- $229.41
- 12 months
- +56.5%
- Market value
- $187B
- Last close
- $150.43
- 12 months
- +28.4%
At a glance
- By market value, Gilead Sciences ($186.5B) is about 5.5 times Biogen ($33.9B).
- Over the last 12 months Biogen's share price moved +56.5% and Gilead Sciences's +28.4%; against the S&P 500 that is +37.4 points and +9.2 points.
- In their last fiscal years Biogen kept 13.1% of revenue as net income and Gilead Sciences 28.9%.
- In the last 90 days insiders reported 0 open-market purchases at Biogen and 0 at Gilead Sciences; members of Congress disclosed 3 trades in Biogen and 1 in Gilead Sciences.
- Next results: Biogen Oct 28, 2026, Gilead Sciences Oct 22, 2026.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Biogen BIIBNASDAQ · Biotechnology | Gilead Sciences GILDNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $33.9B | $187B |
| Revenue, last fiscal year | $9.89B | $29.4B |
| Net income, last fiscal year | $1.29B | $8.51B |
| Net marginNet income as a share of revenue | 13.1% | 28.9% |
| Free cash flow | $2.05B | $9.46B |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Common questions
How do Biogen and Gilead Sciences compare in size?
Gilead Sciences has the larger market value: Biogen $33.9B and Gilead Sciences $187B, at the last close.
Whose share price rose more over the last 12 months, BIIB or GILD?
Over the last 12 months Biogen moved +56.5% and Gilead Sciences +28.4%. Past price moves say nothing about the future.
Which has had more insider buying, Biogen or Gilead Sciences?
Since 2006, Biogen insiders reported 34 open-market purchases against 8 for Gilead Sciences. These are counts of what was filed, not a view on either stock.
Do members of Congress trade BIIB or GILD?
In the last 12 months, members of Congress disclosed 9 trades in Biogen (BIIB) and 4 in Gilead Sciences (GILD).
When did insiders last buy BIIB and GILD?
Biogen: Feb 18, 2026. Gilead Sciences: Feb 6, 2015.
See the record behind any of these
Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Biogen pageGilead Sciences pageRare insider trades this weekAll comparisons
https://oqro.io/compare/biib-vs-gild
